SCHEMBL5779400

SCHEMBL5779400

Nc1ccc(C(c2ccc(Cl)cc2)c2cccnc2)cc1C(=O)c1cccc(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.54
TRPM8 Q7Z2W7 2/20 0.45
CYP11B1 P15538 1/20 0.43
ALOX15 P16050 2/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PKM P14618 1/20 0.42
CYP3A4 P08684 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP1B1 Q16678 1/20 0.41
CCR9 P51686 1/20 0.41
POLB P06746 1/20 0.41
SUCNR1 Q9BXA5 2/20 0.40
CFTR P13569 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382960 0.79 FNTA (0.52) ALOX15ALDH1A1POLBS1PR2S1PR4
SCHEMBL28232 0.77 CCR9 (0.58) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL6341269 0.75 RECQL (0.60) ALOX15ALDH1A1KMT2APOLB
SCHEMBL10674497 0.74 CYP19A1 (1.00) CYP19A1CYP3A4CFTRSLC6A2SLC6A4
SCHEMBL15646031 0.71 PKM (0.64) ALOX15KDM4EUSP2ALDH1A1NPSR1
SCHEMBL7397552 0.71 CCR9 (0.54) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL14916709 0.70 RECQL (0.50) ALOX15KDM4EALDH1A1CYP3A4KMT2A
SCHEMBL7141524 0.69 NPSR1 (0.52) TRPM8ALOX15KDM4EUSP2ALDH1A1
SCHEMBL29963936 0.68 MAPT (0.65) ALOX15KDM4EALDH1A1MEN1KMT2A
SCHEMBL5740187 0.68 MAPT (0.65) ALOX15KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053105-B2 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-30 US disclosed
EP-1322635-B1 FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2006-03-22 EP disclosed
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-30 US disclosed
EP-1322635-A1 FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024682-A1 FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors FNTA, FNTB, RABGGTB CYP19A1 636/4885TRPM8 4667/4885CYP11B1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.